Sedation and analgesia from prolonged pain and stress during mechanical ventilation in preterm infants: is dexmedetomidine an alternative to current practice?

Shalini Ojha,1,2 Janine Abramson,1 Jon Dorling3

ABSTRACT
Mechanical ventilation is an uncomfortable and potentially painful intervention. Opioids, such as morphine and fentanyl, are used for analgesia and sedation but there is uncertainty whether they reduce pain in mechanically ventilated infants. Moreover, there may be short-term and long-term adverse consequences such as respiratory depression leading to prolonged mechanical ventilation and detrimental long-term neurodevelopmental effects. Despite this, opioids are widely used, possibly due to a lack of alternatives.

Dexmedetomidine, a highly selective alpha-2-adrenergic agonist with analgesic and sedative effects, currently approved for adults, has come into use in newborn infants. It provides analgesia and simulates natural sleep with maintenance of spontaneous breathing and upper airway tone. Although data on pharmacokinetics–pharmacodynamics in preterm infants are scant, observational studies report that using dexmedetomidine in conjunction with opioids/benzodiazepines or on its own can reduce the cumulative exposure to opioids/benzodiazepines. As it does not cause respiratory depression, dexmedetomidine could enable quicker weaning and extubation. Dexmedetomidine has also been suggested as an adjunct to therapeutic hypothermia in hypoxic ischaemic encephalopathy and others have used it in conjunction with opioids/benzodiazepines or on its own to reduce the cumulative exposure to opioids/benzodiazepines. As it does not cause respiratory depression, dexmedetomidine could enable quicker weaning and extubation. Dexmedetomidine has also been suggested as an adjunct to therapeutic hypothermia in hypoxic ischaemic encephalopathy and others have used it in conjunction with opioids/benzodiazepines or on its own to reduce the cumulative exposure to opioids/benzodiazepines. As it does not cause respiratory depression, dexmedetomidine could enable quicker weaning and extubation.

Evidence suggests that opioids may be ineffective analgesics and there may be adverse consequences such as respiratory depression and detrimental long-term neurodevelopmental effects.

Dexmedetomidine, a highly selective alpha-2-adrenergic agonist, provides analgesia and simulates natural sleep with maintenance of spontaneous breathing and upper airway tone.

Emerging observational studies suggest that dexmedetomidine use in mechanically ventilated infants may reduce exposure to opioids/benzodiazepines and enable quicker weaning and extubation.

Data on safety and efficacy are scant. Adequately powered randomised controlled trials investigating use of dexmedetomidine in preterm infants are required.

Key messages

⇒ Mechanical ventilation is a potentially painful intervention. Opioids and benzodiazepines are widely used to provide analgesia and sedation in mechanically ventilated infants.

⇒ Evidence suggests that opioids may be ineffective analgesics and there may be adverse consequences such as respiratory depression and detrimental long-term neurodevelopmental effects.

⇒ Dexmedetomidine, a highly selective alpha-2-adrenergic agonist, provides analgesia and simulates natural sleep with maintenance of spontaneous breathing and upper airway tone.

⇒ Emerging observational studies suggest that dexmedetomidine use in mechanically ventilated infants may reduce exposure to opioids/benzodiazepines and enable quicker weaning and extubation.

⇒ Data on safety and efficacy are scant. Adequately powered randomised controlled trials investigating use of dexmedetomidine in preterm infants are required.

INTRODUCTION
Mechanical ventilation via a tracheal tube is widely used for respiratory support in preterm infants. In England and Wales, despite the increase in use of non-invasive respiratory support, 57% of very preterm infants were mechanically ventilated on the day of birth and many others require ventilatory support later in the course of their care.1 This included 91% of extremely preterm infants and the increasing survival of those born at these gestations could lead to further increases in the use of mechanical ventilation in neonatal care.

It is now well accepted that preterm infants perceive pain. Mechanical ventilation is an uncomfortable and painful intervention. Ventilated infants are, often, also subjected to multiple painful procedures and experience...
pain caused by underlying diseases such as necrotising enterocolitis (NEC). Pain and stress cause cardiorespiratory instability including interference with the ventilator synchronising with the infant’s breathing efforts that lead to suboptimal ventilation, fluctuations in heart rate (HR), respiratory rate, blood pressure (BP) and oxygen saturation with complications such as intraventricular haemorrhages (IVH) and metabolic instability.

PAIN IN PRETERM INFANTS
Preterm infants have enhanced hormonal and physiological responses to pain. Anand et al showed that preterm infants undergoing patent ductus arteriosus surgery who did not receive fentanyl had a significantly higher hormonal stress response compared with those who received fentanyl. More recently, MRI studies identified that exposure to pain and stress in neonatal care alters corticospinal tract, and subcortical white matter development with further evidence of reduced volume of the somatosensory thalamus and changes in the cortex, limbic system and basal ganglia, and the white matter that persist into school age.

Management of pain and agitation is fundamental to good intensive care, yet neonatal pain is inconsistently assessed and inadequately managed. A prospective cohort study of 243 European neonatal intensive care units (NICUs), the European Pain Audit in Neonates (EUROPAIN), reported 34% of admissions, including 82% of those who were mechanically ventilated, received some sedation or analgesia. A retrospective cohort study from 348 Pediatrix Medical Group NICUs in the USA found that infants received a sedative, analgesic or paralytic only on 33% of days that they were mechanically ventilated.

Although optimal management of pain and sedation during mechanical ventilation is as yet undiscovered, selective use of continuous infusion of opioids is recommended for infants who are mechanically ventilated for prolonged periods. These recommendations stand despite the 2021 update of the Cochrane review that concluded that there is uncertainty whether opioids have any effect on reducing pain in mechanically ventilated infants. In addition, there may be short-term and long-term adverse consequences of morphine infusion in preterm infants such as respiratory depression leading to prolonged duration of mechanical ventilation and detrimental long-term neurodevelopmental effects. The Cochrane systematic review includes one trial that reported neurodevelopment at 18–24 months: (RR 2.00, 95% CI 0.39 to 10.29; 78 participants); and one study that reported neurodevelopment outcomes at 5–6 years of age: (RR 1.60, 95% CI 0.56 to 4.56; 95 participants) and concluded the evidence was uncertain. Puia-Dumitrescu et al performed a post hoc analysis of infants who participated in the Preterm Erythropoietin Neuroprotection Trial to investigate the effect of exposure to opioids and benzodiazepines on development at 22–26 months’ corrected age. Of the 936 extremely preterm infants 481 (51%) received opioids; 297 (32%) received both opioids and benzodiazepines; and 20 (2%) received benzodiazepines only. Infants exposed to both groups of drugs had more comorbidities compared with those exposed to only one or none with higher adjusted odds of IVH, NEC, severe bronchopulmonary dysplasia, and retinopathy of prematurity, and longer length of hospital stay. Outcomes at 2 years were negatively associated with the combined use of opioids and benzodiazepines even after adjusting for potential confounders. The lowest scores were noted among the infants who received the drugs for more than 7 days (median (IQR) score of 85 (73–97)) compared with 97 (91–107) in infants with no exposure. However, this was not a randomised allocation and the higher prevalence of multiple comorbidities in the group that received drugs makes it difficult to interpret the results.

Despite these uncertainties, opioids are the most popular choice for management of pain and sedation in mechanically ventilated infants. Of the 2142 mechanically ventilated infants included in the EUROPAIN audit, morphine and fentanyl were given to 923 (43%) and 639 (29%) infants, respectively, while 536 (25%) received midazolam. Zimmerman et al similarly reported that in 433,587 ventilated-days, fentanyl (17%), midazolam (14%) and morphine (9%) were the most frequently administered drugs. They also reported increase in administration of opioids during mechanical ventilation from 5% of ventilated days in 1997 to 32% in 2012. In the UK, the percentage of very preterm infants who receive intravenous morphine increased from 32% in 2010 to 37% in 2017.

DEXMEDETOMIDINE: AN ALTERNATIVE AGENT FOR PAIN AND SEDATION IN NEWBORN INFANTS
This high use of opioids despite the uncertainty about benefit and harm is possibly due to a lack of alternative agents that could provide adequate and safe sedation and analgesia in newborn infants. Recently, dexmedetomidine, a highly selective alpha-2-adrenergic agonist (1620:1:α2:α1 specificity) with sedative and analgesic effects, has come into use in newborn infants receiving mechanical ventilation. Several recent studies have explored the off-label use of dexmedetomidine in newborn infants for sedation and analgesia in NICU settings. A summary of the studies is given in tables 1–4. Dexmedetomidine, first approved by the USA Food and Drug Administration in 1999, is similarly authorised by the European Medicine Agency for use for sedation in adult intensive care unit patients requiring sedation level no deeper than arousal in response to verbal stimulation and for sedation of non-intubated patients before and/or during diagnostic or surgical procedures requiring sedation. It provides analgesia via inhibition of substance P release from the dorsal horns of the spinal cord while the anxiolysis and sedation are believed to be
due to the reduction in sympathetic outflow from the locus coeruleus.\textsuperscript{16} It stimulates the natural sleep pathways and induces activity similar to non-rapid eye movement sleep in adults and children.\textsuperscript{17} The effects on respiration and airway also mimic natural sleep and therefore maintain spontaneous breathing and upper airway tone.\textsuperscript{17}

Although there are no data to examine the early exposure to dexmedetomidine and long-term neurocognitive function in children, animal studies suggest that dexmedetomidine may have some neuroprotective effects including cell-protective effects under ischemic conditions and after traumatic brain injury.\textsuperscript{18} In rodents, cortical and white matter loss after hypoxic ischemic injury may be prevented by dexmedetomidine.\textsuperscript{19} In another rat model, brain tissue and cell loss induced by hypoxia-ischemia were attenuated by dexmedetomidine post-conditioning, an effect that was inhibited by \(\alpha_2\)-adrenergic antagonists suggesting that the protective

\begin{table}
\centering
\begin{tabular}{|c|c|c|c|c|c|c|}
\hline
Reference & Setting & Study design & Inclusion criteria & Dexmedetomidine group & Comparator & Outcomes & Notes \\
\hline
O’Mara 2012\textsuperscript{28} & USA & Retrospective case–control January 2005–May 2010 & <36 weeks’ GA at birth, <2 weeks of life at study entry and receiving mechanical ventilation & N=24
GA: 25.5±0.1.7
BW: 832±0.204.2 g & Fentanyl
N=24
GA: 24.9±0.1.6
BW: 675±0.164.2 & Dexmedetomidine group had ▶ Shorter duration of treatment (12.5 vs 20 days) ▶ Similar no of sedative boluses per day (1.7 vs 3) but in total less total additional sedation ▶ More no of days free of additional sedation ▶ Reduction in no of days on mechanical ventilation (14.4 (7.3) vs 28.4 (9.9)) ▶ Better GI function in including earlier establishment of full feeds ▶ Less late onset sepsis & \\
\hline
Sellas 2019\textsuperscript{32} & USA & Retrospective cohort study with matched controls January 2010 to August 2015 & Invasive surgical procedure Required at least 6 hours of continuous sedation and/or analgesia & Received dexmedetomidine in addition to opioids N=39
GA: 37 (29–39)
PMA at surgery:39 (29–59) weeks & Opioids only (morphine or fentanyl)
N=39
GA: 37 (27–38)
PMA at surgery: 37 (27–41) & 28/39 (72%) of those who received dexmedetomidine also received opioids Dexmedetomidine group had ▶ More episodes of bradycardia (12.8% vs 5.1%; \(p=0.01\)) ▶ No difference in episodes of hypotension or respiratory depression. ▶ Lower cumulative dose of opioids (1155 \(\mu\)g/kg vs 1841 \(\mu\)g/kg; \(p=0.01\)) ▶ No difference in the no of supplemental doses of opioids & \\
\hline
Morton 2021\textsuperscript{39} & USA & QI initiative to reduce benzodiazepine exposure during Pre-QI: January 2015 to February 2018 Post-QI March 2018: to December 2019 & At least 35 weeks’ PMA <14 days of sedation Sedation needed for mechanical ventilation & Guideline and QI initiative to promote use of escalating dose of dexmedetomidine & Midazolam and no specific guideline for dexmedetomidine use & Proportion of infants receiving any dexmedetomidine increased from 18% to 49%
Infants receiving only dexmedetomidine increased from 3% to 33%
Infants receiving any midazolam decreased from 95% to 65%
Infants who received dexmedetomidine received less daily midazolam (1.3 mg/kg/day vs 2.2 mg/kg/day) Increase in midazolam-free days No difference in mean duration of sedation episodes & \\
\end{tabular}
\caption{Summary of clinical studies of dexmedetomidine in newborn infants: studies with a comparator group that did not receive any dexmedetomidine}
\end{table}
| Study ID Setting | Study design | Inclusion criteria | Intervention | Outcomes |
|------------------|--------------|--------------------|--------------|----------|
| Chrysostomou 2014 USA eleven centres<sup>39</sup> | Phase II/III, open-label, multicentre safety, efficacy, and PK trial | Intubated and mechanically ventilated neonates GA ≥28 to ≤44 weeks anticipated to require a minimum of 6 hours of continuous IV sedation excluded <1 kg infants | Dosing: 3 phases level 1: loading dose (LD), 0.05 mg/kg; maintenance dose (MD), 0.05 mg/kg/hour level 2: LD, 0.1 mg/kg; MD, 0.1 mg/kg/hour level 3: LD, 0.2 mg/kg; MD, 0.2 mg/kg/hour. N=42 (18 preterm; 24 term) N-PASS tool for need of sedation and analgesia | Need for additional sedation: no preterms; 4 term (midazolam) Need for additional analgesia: 17 (40%) – 3 preterms (fentanyl); 14 term (fentanyl and/or morphine) N-PASS scores: 5% >= 3 in pain; 77% between -5 and +3 (adequate) and 18% <= -6 deep sedation HR decreased by an average of 12% ± 9% at 7.7 ± 7.3 hour, and systolic BP decreased by 14% ± 12% at 6.5 ± 7 hour Other adverse effects: 26 (62%) patients (11 preterm and 15 term) – diastolic hypotension, hypertension, agitation, respiratory acidosis. No discontinuation, no significant lab or ECG abnormalities |
| Estkowski 2015 USA PICU Single centre<sup>36</sup> | Retrospective chart review October 2007 to Aug 2012 | At least 37 weeks PMA | Compared neonates (up to 28 days of CGA) to infants (28d CGA to 1 year) Neonates: N=28 (13 born preterm) Infants: N=99 | Neonates as compared with infants had:  ► Similar minimum infusion rates  ► Lower median maximum dosage: 0.4 μg/kg/hour (IQR, 0.26–0.6) vs 0.6 μg/kg/hour (IQR, 0.4–0.8) (p<0.01)  ► Similar duration of use: 41 (17–76) hr  ► Fewer had any episode of bradycardia: 2/28 (7%) vs 55/99 (56%) (p<0.01)  ► Similar incidence of hypotension: 4/28 (14%) vs 30/99 (30%) (p=0.15) In neonates: 3/28 (11%) received a fluid bolus 4/28 (14%) dexmedetomidine discontinued due to cardiovascular adverse effects In infants: 3/99 discontinued infusion due to bradycardia 75/99 (76%) had additional sedative agents |
| Dersch-Mills 2019 Canada Single centre (outborn NICU)<sup>38</sup> | Retrospective observational study December 2014 to December 2016 | Received dexmedetomidine for ≥3 hours | N=38 (30 for surgery) GA: 37.1 (30.7–38.3) 17 preterms; 41 (6–74) days old) BW: 2605 (1721–3212) used for mean (range): 11.1 (0.13–58) days most (36/38) received concomitant opioid infusion, mostly fentanyl | 32/38, at least one adverse effect  ► 15, hypotension  ► 25 bradycardia (drop of ≥20 bpm from baseline)  ► 7 severe bradycardia (drop of ≥40 bpm from baseline)  ► No dose adjustment or discontinuation for any adverse effect Withdrawal: 22/38 had tachycardia and increase NAS scores |

BP, blood pressure; CGA, corrected gestational age; GA, gestational age; IV, inverse variance; NAS, Neonatal Abstinence Syndrome; NICU, neonatal intensive care unit; N-PASS, Neonatal Pain and Sedation Scale; PICU, paediatric intensive care unit; PK, pharmacokinetics; PMA, postmenstrual ages.
The evaluation of pharmacokinetics (PK), pharmacodynamics (PD), efficacy and safety of drugs in vulnerable newborn infants is challenging.\textsuperscript{24} Dexmedetomidine is metabolised via glucuronidation, hydroxylation (via CYP2A6) and N-methylation and primarily eliminated via the urine.\textsuperscript{25} As these pathways, particularly glucuronidation, are immature in the first year after birth, dexametomidine clearance may be decreased but there is a lack of PK-PD studies in preterm infants.\textsuperscript{17}

The therapeutic window for dexametomidine in older children is 0.4–0.8 μg/L (optimum level around 0.6 μg/L)\textsuperscript{26} with a safety measure of maintaining plasma concentrations below 1 μg/L and is assumed to be the same in neonatal studies.\textsuperscript{24} The clinical applicability of these serum concentrations is not yet determined and surrogate markers of efficacy such as pain and sedation scores are used to determine clinical utility and titrate dosing.\textsuperscript{27} The drug is available as dexametomidine hydrochloride (100 μg/mL or 4 μg/mL),\textsuperscript{28} usually delivered in a concentration of 0.5–1 μg/mL as a loading dose (LD) over 10–20 min and maintenance dose (MD) as continuous infusion using rate-controlled syringe pumps. In a phase II/III open-label, safety, efficacy and PK trial including 11 centres, Chrysostomou \textit{et al} investigated three escalating dose regimens (LD followed by MD) of dexametomidine mechanically ventilated 28–44 weeks’ GA infants.\textsuperscript{29} In 42 infants (18 preterm and 24 term-born), they found that additional sedation (midazolam) was required only in 4 infants (all term-born) while additional analgesia (fentanyl or morphine) was required in 17 infants (3 preterms and 14 term-born). Using the Neonatal Pain and Sedation Scale (N-PASS), they found that at all three dose levels, infants had signs of pain or agitation (N-PASS score >3) at 5% time points only. Preterm infants, as compared with term infants, had lower weight-adjusted plasma clearance (0.3 vs 0.9 L/hour/kg) and increased elimination half-life (7.6 vs 3.2 hours). Van Dijkman \textit{et al} performed a dose-finding study of dexametomidine in mechanically ventilated newborn infants who received dexametomidine infusion over 24 hours.

**Pharmacological Studies on Dexmedetomidine in Newborn Infants**

The evaluation of pharmacokinetics (PK), pharmacodynamics (PD), efficacy and safety of drugs in vulnerable newborn infants is challenging.\textsuperscript{24} Dexmedetomidine is metabolised via glucuronidation, hydroxylation (via CYP2A6) and N-methylation and primarily eliminated via the urine.\textsuperscript{25} As these pathways, particularly glucuronidation, are immature in the first year after birth, dexametomidine clearance may be decreased but there is a lack of PK-PD studies in preterm infants.\textsuperscript{17}

The therapeutic window for dexametomidine in older children is 0.4–0.8 μg/L (optimum level around 0.6 μg/L)\textsuperscript{26} with a safety measure of maintaining plasma concentrations below 1 μg/L and is assumed to be the same in neonatal studies.\textsuperscript{24} The clinical applicability of these serum concentrations is not yet determined and surrogate markers of efficacy such as pain and sedation scores are used to determine clinical utility and titrate dosing.\textsuperscript{27} The drug is available as dexametomidine hydrochloride (100 μg/mL or 4 μg/mL),\textsuperscript{28} usually delivered in a concentration of 0.5–1 μg/mL as a loading dose (LD) over 10–20 min and maintenance dose (MD) as continuous infusion using rate-controlled syringe pumps. In a phase II/III open-label, safety, efficacy and PK trial including 11 centres, Chrysostomou \textit{et al} investigated three escalating dose regimens (LD followed by MD) of dexametomidine mechanically ventilated 28–44 weeks’ GA infants.\textsuperscript{29} In 42 infants (18 preterm and 24 term-born), they found that additional sedation (midazolam) was required only in 4 infants (all term-born) while additional analgesia (fentanyl or morphine) was required in 17 infants (3 preterms and 14 term-born). Using the Neonatal Pain and Sedation Scale (N-PASS), they found that at all three dose levels, infants had signs of pain or agitation (N-PASS score >3) at 5% time points only. Preterm infants, as compared with term infants, had lower weight-adjusted plasma clearance (0.3 vs 0.9 L/hour/kg) and increased elimination half-life (7.6 vs 3.2 hours). Van Dijkman \textit{et al} performed a dose-finding study of dexametomidine in mechanically ventilated newborn infants who received dexametomidine infusion over 24 hours.

**Table 3** Summary of case reports of dexametomidine in newborn infants

| Reference setting | Case description | outcomes | Notes |
|-------------------|------------------|----------|-------|
| Finkel 2007 USA\textsuperscript{21} | 2 days old, 3 kg female<br>Repair of bladder extrophy<br>Received dexmedetomidine infusion | Hypothermia and bradycardia—at 0.4 μg/kg/hour<br>dose reduced and maintained on 0.2 μg/kg/hour<br>without further adverse events | |
| O’Mara 2009 USA\textsuperscript{16} | 24 weeks GA, 9 days old infant on high frequency<br>oscillatory ventilation. Was on fentanyl and lorazepam<br>Started at 0.5 μg/kg over 10 min followed by 0.25 μg/kg/hour<br>increased by 0.05–0.1 μg/kg/hour every 12 hours if needed. Max rate of 0.7 μg/kg/hour for 19 days. | Calmed and remained sedated<br>Allowed weaning of ventilation and extubation | |
| Kubota 2012 Japan\textsuperscript{44} | Term infant—ventilated | EEG confirmed seizures, stopped 12 hours after discontinuation of dexametomidine infusion<br>without any antiepileptic medication<br>Normal development | |

EEG, electroencephalogram; GA, gestational age; HIE, hypoxic ischaemic encephalopathy; NICHD, Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Initial dosing (0.3 μg/kg/hour) was determined by extrapolation of previously published PK of dexmedetomidine in older children and was subsequently increased to 0.4 μg/kg/hour in the follow-up phase due to higher clearance of the drug. Additional sedation was required in 83% of the participants as indicated by Comfort-neo scores. In seven term infants with hypoxic ischaemic encephalopathy (HIE) and therapeutic hypothermia (TH), McAdams et al found that dexmedetomidine clearance was either comparable or lower but volume of distribution was larger compared with estimates in normothermic infants. They recommended doses up to 0.4 μg/kg/hour and that a LD may be needed to achieve therapeutic concentration without a lag. Dose regimens used in published clinical studies of preterm infants and available neonatal formularies are given in Table 5.

**Table 4** Clinical studies of use of dexmedetomidine in infants undergoing therapeutic hypothermia for HIE

| Study ID setting | Study design | Inclusion criteria | Dexmedetomidine group | Comparator | Outcomes notes |
|------------------|-------------|--------------------|-----------------------|------------|----------------|
| O’Mara 2018 USA Single centre | Retrospective cohort study July 2013 to October 2016 | HIE requiring TH Received dexmedetomidine for 48 hours | N=19 2, dexmedetomidine only; 17, combination with fentanyl | No comparator | Fentanyl weaned down in 13/17 after starting dexmedetomidine 10 infants required inotropes. Initiation of dexmedetomidine did not affect HR, or BP. One infant had bradycardia – resolved with discontinuation of fentanyl Clinical outcomes: 1 died; 8 had seizures |
| Cosnahan 2021 USA single centre | Retrospective cohort study January 2018 to April 2020 | HIE requiring TH (NICHD criteria) | March 2019-April 2020 N=34 Continuous dexmedetomidine 0.3 μg/kg/hour with increments of 0.1 μg/kg/hour based on pain scores and breakthrough morphine dose requirements Maximum: 2 μg/kg/hour | January 2018-March 2019 N=36 Intermittent morphine 0.1 mg/kg every 4 hours | No difference in N-PASS scores Dexmedetomidine group had: ► Higher breakthrough morphine requirement: 0.13 (0.13) vs 0.04 (0.09) mg/kg, p=0.001 ► Lower total morphine requirement: 0.13 (0.13) vs 1.79 (0.23) mg/kg, p<0.0001 ► Reduced respiratory support requirement ► Similar outcomes for feeding, EEG and MRI scan All HR measurement in normal range ► morphine group had higher HR and BP at some timepoints |
| Elliot 2022 abstract only USA Single centre | Retrospective cohort 2011–2019 | Dexametomidine and/or fentanyl | Dexmedetomidine=46 Fentanyl=120 (14 monotherapy; 32 in combination) | Dexametomidine group had lower HR: 91±9 vs 103±11 bpm Dexametomidine was reduced or discontinued in 22 (48%) due to inadequate sedation with low HR |

BP, blood pressure; HIE, hypoxic ischaemic encephalopathy; HR, heart rate; N-PASS, Neonatal Pain and Sedation Scale; TH, therapeutic hypothermia.

**CLINICAL REPORTS OF THE USE OF DEXMEDETOMIDINE IN PRETERM INFANTS**

Case reports of dexmedetomidine use to sedate a difficult to ventilate 24 weeks’ GA infant and others reporting adverse effects were followed by larger single-centre studies. Use has been reported in extremely preterm
| Study ID                  | Bolus at start of infusion | Infusion Starting dose | Increments | Range/maximum | Weaning                                    |
|--------------------------|----------------------------|------------------------|------------|---------------|--------------------------------------------|
| O’Mara 2012<sup>28</sup> | 0.5 μg/kg                  | 0.3 μg/kg/hour         | 0.1 μg/kg/hour twice daily if need for >3 doses of adjunct sedation | 0.3–1.2 μg/kg/hour | 0.1 μg/kg/hour every 12–24 hours           |
| Morton 2021<sup>39</sup> | –                          | 0.5 μg/kg              | 0.1–0.2 μg/kg/hour not more frequently than every 30 min | Two μg/kg/hour     | No specific regimen given                  |
| Estkowski 2015<sup>26</sup> | –                          | –                      | –          | –             | –                                          |
| Dersch-Mills 2019<sup>33</sup> | –                          | 0.2–0.3 μg/kg/hour     | 0.1 μg/kg/hour based on pain and sedation scores | 0.5 μg/kg/hour     | No regimen specified—weaned over median of 79 hours (IQR, 35–175). 10 infants needed clonidine (nine had dexmedetomidine for >10 days) |
| Australasian Neonatal Medicines Formulary<sup>45</sup> | <37 weeks’ GA Term infant ≤14 days | 0.2 μg/kg 0.35 μg/kg | 0.1–0.2 μg/kg/hour every 30 min 1.2 μg/kg/hour | One μg/kg/hour One μg/kg/hour every 30 min OR 0.2 μg/kg/hour every 8 hours |
|                           | Term infant >14 days       | 0.5 μg/kg 0.5 μg/kg/hour | 1.5 μg/kg/hour | –             | –                                          |
| Neonatal Drug Dosing Guideline, Izaak Walton Killam Health Centre (personal communication) | 0.5–1 μg/kg ‘not usually required’ | 0.1 to 0.3 μg/kg/hour | 0.1 μg/kg/hour every 1–2 hours | One μg/kg/hour | 0.1 μg/kg/hour every 12–24 hours as tolerated |
infants in the first weeks after birth, in preterm infants at later postmenstrual ages (PMA) and term-born infants, after surgical procedures, and in infants undergoing TH for hypoxic ischaemic encephalopathy (HIE). It is also used for sedation during procedures such as MRI. In an update of medication prescribing patterns in the US NICUs, Stark et al reported that between 2010 and 2018, dexmedetomidine was ninth in the list of drugs that had the greatest relative increase in use and had become the 90th most frequently prescribed medication although its use was not reported, at least until 2017, in neonatal care in the UK.

Dexmedetomidine is used for sedation and analgesia on its own or in combination with other agents with the aim of reducing cumulative exposure to opioids and benzodiazepines. Comparing 48 infants with a mean GA of 25 weeks who received either fentanyl or dexmedetomidine, O’Mara et al found that the dexmedetomidine group required less adjunctive sedation.

Comparing 39 infants who received dexmedetomidine, (including 28 who concomitantly received opioid infusion) with 39 matched controls who only received opioids, Sellas et al found that there was no difference in the duration of use or the number of doses of opioids but the total dose of opioids received was lower in the group that received dexmedetomidine. With an aim to reduce benzodiazepine exposure in infants who were at least 35 weeks’ PMA and needed sedation for mechanical ventilation, Morton et al implemented a quality improvement project with a sedation guideline recommending the use of dexmedetomidine as initial agent or in addition to midazolam. They demonstrated reduction in use of midazolam with fewer infants receiving midazolam, increased midazolam-free days and lower daily midazolam doses in those who received additional dexmedetomidine without any increase in the mean duration of sedation episodes. In 38 infants at a median PMA of 38.8 weeks, of whom 30 were postsurgical, Dersch-Mills et al found that the opioid infusion was reduced within 24 hours of initiation of dexmedetomidine in 12 of the 18 infants who were on concomitant opioids.

As dexmedetomidine does not cause respiratory depression, it is postulated that its use with no or reduced doses of opioids should enable quicker weaning off mechanical ventilation and support extubation. O’Mara et al found a significantly shorter duration of mechanical ventilation in those who received dexmedetomidine compared with those on fentanyl only (mean±SD: 14.4±7.3 vs 28.4±9.9; p<0.0001). They also reported that clinicians extubated 19 of 28 infants who received dexmedetomidine while receiving infusion of the drug at the time of extubation. Due to the early extubation, fewer infants received dexamethasone (4 vs 11) and there were fewer chest X-rays performed (mean±SD: 28±8.8 vs 49±13.8) in the dexmedetomidine group compared with those who received fentanyl.

The main concerns with dexmedetomidine use are bradycardia and hypotension. In the general adult population, bradycardia is reported in 5%–42% and hypotension in 24%–56% of those who receive dexmedetomidine. Chrysostomou et al found, in 42 neonates, that the HR decreased by an average of 12%±9% and systolic BP decreased by 14%±12% at 6–7 hours of starting the dexmedetomidine infusion. Although mostly reported to be not of clinical significance, dexmedetomidine can induce reduction in HR and BP. Dersch-Mills et al analysed adverse effects in 38 infants, 36 of whom were also receiving opioid infusion and found that 25 had at least one episode of bradycardia (drop of >20 bpm from baseline lasting for >2 hours) including 7 who had a drop of >40 bpm. Hypotension occurred in 15 infants. Dopamine was used concurrently in 17 infants of which 5 were started on dopamine after the initiation of dexmedetomidine. No infants had dexmedetomidine infusion discontinued due to adverse effects. Similarly, Sellas et al found that 5 of 39 infants who received dexmedetomidine experienced episodes of bradycardia as compared with 2 of 39 in the no-dexmedetomidine group although all episodes were self-limiting and did not require any intervention. O’Mara et al measured BP and HR hourly and did not see any appreciable effect on either in those on dexmedetomidine compared with the infants on fentanyl and Morton et al reported that following their initiative to increase use of dexmedetomidine in mechanically ventilated infants, one infant had dexmedetomidine discontinued due to bradycardia without haemodynamic compromise however discontinuing the drug did not resolve the bradycardia. Estkowski et al compared neonates in a paediatric intensive care unit with older infants and found that among the 28 neonates, 4 experienced hypotension and 2 had bradycardia as compared with 30 and 55 of 99 infants who had hypotension and bradycardia, respectively. Three neonates required fluid bolus, one had dopamine infusion started after dexmedetomidine and four had dexmedetomidine discontinued due to adverse events.

There are no reports of additional adverse events due to dexmedetomidine interacting with other drugs when used in neonatal care, however, polypharmacy is common in neonatal practice and dexmedetomidine can, potentially interact with other frequently used drugs such as phenobarbitone (additional central nervous system depression) and others such as, beta-blockers and diazoxide (worsening of bradycardia and hypotension).

CONCLUSIONS AND RECOMMENDATIONS
Emerging clinical data suggest that dexmedetomidine may be an alternative to opioids and benzodiazepines for managing pain and sedation in mechanically ventilated newborn infants. It may help reduce the exposure to these agents and as it does not cause respiratory depression, it may facilitate quicker extubation. The potential neuroprotective effect on the immature brain could ease the concerns about the impact of pain and stress and that of opioids and benzodiazepines on the developing
| Study ID | Study design | Eligibility | Intervention | Comparator | Outcomes |
|----------|--------------|-------------|--------------|------------|----------|
| NCT04820101 | Single group assignment Open label Sample size=40 | Inclusion criteria:<ul><li>GA 26–36 weeks’</li><li>Respiratory distress syndrome requiring surfactant therapy</li></ul>Exclusion criteria:<ul><li>Need for emergency intubation in the delivery room</li><li>Major congenital malformations or chromosomal anomaly abnormalities</li><li>Fetal hydrops</li><li>Hypercapnia</li><li>Pneumothorax</li><li>Haemodynamic compromise</li></ul> | Dexmedetomidine one μg/kg slowly IV over 10 min | None | Change in Neonatal Infants Pain Scale score before, during and immediately after the procedure In 24 hours, <ul><li>No of apnoea</li><li>No of severe apnoea</li><li>Need for ventilation</li></ul> |
| NCT04772222 | Randomised controlled trial Parallel 1:1 allocation Open label Sample size=50 | ≥36 weeks’ GA with HIE treated with TH. Requiring sedation and/or treatment to prevent shivering during TH as assessed by the Neonatal Pain, Agitation, and Sedation Scale scores and a modified Bedside Shivering Assessment Scale. | Dexmedetomidine Loading dose of 1 μg/kg followed by 0.1–0.5 μg/kg/hour continuous infusion | Morphine Intermittent dosing every 3–4 hours of 0.02–0.05 mg/kg/dose or continuous infusion of 0.005–0.01 mg/kg/hour | Safety – potential adverse events such as hypotension, hypertension, bradycardia, cardiac arrhythmias, hypothermia, acute renal failure, liver failure, seizures Shivering Days to full oral feeding Mother assessment at 7 days, 3–4 mo Neurological assessment at 3–4 months and 6–9 months |

GA, gestational age; IV, inverse variance; TH, therapeutic hypothermia.
brain although other reports suggest that dexmedetomidine could also adversely impact the newborn brain. Despite the creeping acceptance of its use in this population, there are no robust data to demonstrate either the efficacy or the safety of this drug in preterm infants. The studies discussed above are observational and mostly retrospective chart reviews. It is encouraging to see robust PK-PD studies focussing on determining the optimal dose regimens. The initial results demonstrating PK differences between term and preterm infants suggest that further population PK-PD studies are required. A Cochrane systematic review was registered in 2016 but there are no completed randomised controlled trials (RCTs) or systematic reviews of use of dexmedetomidine in preterm infants. The increasing number of publications of observational studies and use in clinical practice as seen by the availability of neonatal drug formulares for its use demonstrat evolving practice that dexmedetomidine is being used in newborn infants in neonatal units. The data on safety and efficacy are scant and not of high quality and there are no data on long-term neurodevelopmental impact on preterm or term-born infants. We found one registered pilot RCT in term infants undergoing TH for HIE and one investigating the use of bolus dose for supporting less invasive surfactant administration in preterm infants (table 6).

The acceptance of dexmedetomidine in routine clinical practice must be preceded by clinical evidence. While there is a suggestion that dexmedetomidine may be the agent that could provide analgesia and sedation with minimal adverse impacts, the available data are not sufficient to ensure that it is safer than the alternatives used in current practice. Although all currently used sedatives and analgesics have adverse impact on the preterm brain, new agents must be investigated thoroughly before being accepted as standard practice. We need adequately powered and well-designed RCTs investigating whether dexmedetomidine alone or in conjunction with opioids/benzodiazepines in preterm infants who require analgesia and sedation during mechanical ventilation reduces the need for opioids/benzodiazepine and improves neurodevelopment at 24 months and later as compared with the use of opioids/benzodiazepines alone.

Twitter Shalini Ojha @shaliniojha7
Contributors SO and JD conceived the piece. SO led the write up. JA conducted the literature search and completed the study summaries. SO, JD and JA revised and approved the final manuscript. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests SO has received funds from the National Institute of Health Research, UK and the Medical Research Council, UK for other research. JD has received funds from the National Institute of Health Research, UK, Canadian Institute for Health Research, Canada, Nova Scotia Research, Canada and Action Medical Research, UK for other research

Patient consent for publication Not applicable.

Provenance and peer review Commissioned; externally peer reviewed.

REFERENCES

1. Sand L, Szatkovski L, Kwok T, Ng Chang, et al. Observational cohort study of changing trends in non-invasive ventilation in very preterm infants and associations with clinical outcomes. Arch Dis Child Fetal Neonatal Ed 2022;107:150–5.

2. Bellu R, Romanstik O, Nava C, et al. Opioids for newborn infants receiving mechanical ventilation. Cochrane Database Syst Rev 2021;3:D001371.

3. COMMITTEE ON FETUS AND NEWBORN and SECTION ON ANESTHESIOLOGY AND PAIN MEDICINE. Prevention and management of procedural pain in the neonate: an update. Pediatrics 2016;137:e20154271.

4. Anand KJ. Clinical importance of pain and stress in preterm neonates. Biol Neonate 1998;73:1–9.

5. Anand KJ, Sippell WG, Aynsley-Green A. Randomised trial of fentanyl anaesthesia in preterm babies undergoing surgery: effects on the stress response. Lancet 1987;1:243–8.

6. McPherson C, Miller SP, El-Dib M, et al. The influence of pain, agitation, and their management on the immature brain. Pediatr Res 2020;88:168–75.

7. Carabajal R, Eriksson M, Courtous E, et al. Sedation and analgesia practices in neonatal intensive care units (EUROFAN): results from a prospective cohort study. Lancet Respir Med 2015;3:796–812.

8. Zimmerman KO, Smith PB, Benjamin DK, et al. Sedation, analgesia, and paralysis during mechanical ventilation of premature infants. J Pediatr 2017;180:99–104.

9. Ancora G, Lago P, Garetti E, et al. Evidence-Based clinical guidelines on analgesia and sedation in newborn infants undergoing assisted ventilation and endotracheal intubation. Acta Paediatr 2019;108:208–17.

10. Ancora G, Lago P, Garetti E, et al. Efficacy and safety of continuous infusion of fentanyl for pain control in preterm newborns on mechanical ventilation. J Pediatr 2013;163:645–51.

11. MacGregor R, Evans D, Sugden D, et al. Outcome at 5–6 years of prematurely born children who received morphine as neonates. Arch Dis Child Fetal Neonatal Ed 1998;73:F40–3.

12. Puia-Dumitrescu M, Comtock BA, Li S, et al. Assessment of 2-year neurodevelopmental outcomes in extremely preterm infants receiving opioids and benzodiazepines. JAMA Netw Open 2021;4:e2115998.

13. Al-Turkait A, Szatkowski L, Choonara I, et al. Drug utilisation in neonatal units in England and Wales: a national cohort study. Eur J Clin Pharmacol 2022;78:697–71.

14. Gertler R, Brown HC, Mitchell DH, et al. Dexmedetomidine: a novel sedative-analgesic agent. Proc 2001;14:13–21.

15. European Medicines Agency. Dexmedetomidine accord. 2022. Available: https://www.ema.europa.eu/en/medicines/human/EPAR/dexmedetomidine-accord#authorisation-details-section [Accessed 11 Feb 2022].

16. O’Marra K, Gal P, Ransommd JL, et al. Successful use of dexmedetomidine for sedation in a 24-week gestational age neonate. Ann Pharmacother 2000;43:1707–13.

17. Mahmoud M, Barbi E, Mason KP. Dexmedetomidine: What’s New for Neonatologists? A Narrative Review. J Clin Med 2020;9:2724.

18. Schoeler M, Loetscher PD, Rossaint R, et al. Dexmedetomidine is neuroprotective in an in vitro model for traumatic brain injury. BMC Neurol 2012;12:20.

19. Cosnahaa AN, Angert RM, Jano E, et al. Dexmedetomidine versus intermittent morphine for sedation of neonates with encephalopathy undergoing therapeutic hypothermia. J Perinatol 2021;41:2284–91.

20. Ren X, Ma H, Zuo Z. Dexmedetomidine postconditioning reduces brain injury after brain hypoxia-ischemia in neonatal rats. J Neuroimmune Pharmacol 2016;11:238–47.

21. Ezzati M, Kawanov G, Rocha-Ferreira E, et al. Dexmedetomidine combined with therapeutic hypothermia is associated with cardiovascular instability and neurotoxicity in a piglet model of perinatal asphyxia. Dev Neurosci 2017;39:156–70.
22 Pancaro C, Segal BS, Sikes RW, et al. Dexmedetomidine and ketamine show distinct patterns of cell degeneration and apoptosis in the developing rat neonatal brain. *J Matern Fetal Neonatal Med* 2016;29:3827–33.

23 Cortes-Ledesma C, Arruza L, Sainz-Villamayor A, et al. Dexmedetomidine affects cerebral activity in preterm infants. *Arch Dis Child Fetal Neonatal Ed* 2022. doi:10.1136/archdischild-2021-332411. [Epub ahead of print: 14 Mar 2022].

24 Duerden EG, Guo T, Dodibia L, et al. Midazolam dose correlates with abnormal hippocampal growth and neurodevelopmental outcome in preterm infants. *Ann Neurol* 2016;79:548–59.

25 van Dijkman SC, De Cock PAJG, Smets K, et al. Dose rationale and pharmacokinetics of dexmedetomidine in mechanically ventilated new-borns: impact of design optimisation. *Eur J Clin Pharmacol* 2019;75:1393–404.

26 Estkowski LM, Morris JL, Sinclair EA. Characterization of dexmedetomidine dosing and safety in neonates and infants. *J Pediatr Pharmacol Ther* 2015;20:112–8.

27 Potts AL, Anderson BJ, Warman GR, et al. Dexmedetomidine pharmacokinetics in pediatric intensive care—a pooled analysis. *Paediatr Anaesth* 2009;19:1119–29.

28 O’Mara K, Gal P, Wimmer J, et al. Dexmedetomidine versus standard therapy with fentanyl for sedation in mechanically ventilated premature neonates. *J Pediatr Pharmacol Ther* 2012;17:252–62.

29 Chrysostomou C, Schulman SR, Herrera Castellanos M, et al. A phase II/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates. *J Pediatr* 2014;164:278–82.

30 McAdams RM, Pak D, Lalovic B, et al. Dexmedetomidine pharmacokinetics in neonates with hypoxic-ischemic encephalopathy receiving hypothermia. *Anesthesiol Res Pract* 2020;2020:1–15.

31 Finkel JC, Quezado ZMN. Hypothermia-Induced bradycardia in a neonate receiving dexmedetomidine. *J Clin Anesth* 2007;19:290–2.

32 Sellas MN, Kyllonen KC, Lepak MR, et al. Dexmedetomidine for the management of postoperative pain and sedation in newborns. *J Pediatr Pharmacol Ther* 2019;24:227–33.

33 Dersch-Mills DA, Banasch HL, Yusuf K, et al. Dexmedetomidine use in a tertiary care NICU: a descriptive study. *Ann Pharmacother* 2019;53:464–70.

34 Elliott M, Burnsed J, Heinan K, et al. Effect of dexmedetomidine on heart rate in neonates with hypoxic ischæmic encephalopathy undergoing therapeutic hypothermia. *J Neonatal Perinatal Med* 2022;15:47–54.

35 O’Mara K, Weiss MD. Dexmedetomidine for sedation of neonates with HIE undergoing therapeutic hypothermia: a single-center experience. *AJP Rep* 2018;8:e168–73.

36 Inserra E, Colella U, Caredda E, et al. Safety and effectiveness of intranasal dexmedetomidine together with midazolam for sedation in neonatal MRI. *Paediatr Anaesth* 2022;32:79–81.

37 Bua J, Massaro M, Cossovel F, et al. Intranasal dexmedetomidine, as midazolam-sparing drug, for MRI in preterm neonates. *Paediatr Anaesth* 2018;28:747–8.

38 Stark A, Smith PB, Hornik CP, et al. Medication Use in the Neonatal Intensive Care Unit and Changes from 2010 to 2018. *J Pediatr* 2022;240:66–71.

39 Morton SU, Labrecque M, Moline M, et al. Reducing benzodiazepine exposure by Instituting a guideline for dexmedetomidine usage in the NICU. *Pediatrics* 2021;148:e2020041566.

40 UpToDate. Lexicomp-UpToDate dexmedetomidine: pediatric drug information. Available: https://www.uptodate.com/contents/table-of-contents/drug-information [Accessed 29 Mar 2022].

41 BNF FOR CHILDREN (BNFC). 2020-2021. *s.l*. PHARMACEUTICAL PRESS, 2020.

42 Ibrahim M, Jones LJ, Lai NM, et al. Dexmedetomidine for analgesia and sedation in newborn infants receiving mechanical ventilation. *Cochrane Database Syst Rev*:118.

43 Barrington K. Dexmedetomidine: new wonder drug or next neonatal disaster? *Neonatal Research*, 2022. Available: https://neonatalresearch.org/2022/03/23/dexmedetomidine-new-wonder-drug-or-next-neonatal-disaster/ [Accessed 19 Apr 2022].

44 Kubota T, Fukasawa T, Kitamura E, et al. Epileptic seizures induced by dexmedetomidine in a neonate. *Brain Dev* 2013;35:360–2.

45 Australasian Neonatal Medicines Formulary. Dexmedetomidine: neonborn use only, 2021. Available: https://www.anmfonline.org/wp-content/uploads/2021/06/dexmedetomidine-18022021-2.0.pdf

46 Baserga M, DuPont TL, Ostrander B, et al. Dexmedetomidine use in infants undergoing cooling due to neonatal encephalopathy (dice trial): a randomized controlled trial: background, aims and study protocol. *Front Pain Res* 2021:2:770511.